<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02356705</url>
  </required_header>
  <id_info>
    <org_study_id>1098</org_study_id>
    <nct_id>NCT02356705</nct_id>
  </id_info>
  <brief_title>Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2</brief_title>
  <official_title>Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bassett Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bassett Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Midazolam is often given before surgery to sedate a patient before anesthesia is given.
      Children are often given a small dose either by mouth or squirted into the nose. Children
      will often spit out the oral midazolam, making it difficult to know how much medicine, if
      any, they have received. Giving midazolam into the nose is more reliable, but children may
      complain of pain, stinging, and may become upset due to the discomfort. Nosebleeds may also
      occur when midazolam is squirted alone into the nose. The purpose of this study is to see if
      adding a numbing medicine, xylocaine, to the nasal midazolam makes giving the midazolam
      easier and more comfortable without affecting how the midazolam works as a sedative. This is
      follow up to the pilot study, Project # 994. This will expand the previous study, with
      additional participants and revised xylocaine concentration
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pediatric Pre-Induction Anesthesia Scale at time of mask placement</measure>
    <time_frame>25 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pediatric Pre-Induction Anesthesia Scale at arrival to operating room</measure>
    <time_frame>20 minutes</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to discharge</measure>
    <time_frame>approximately 3 hours</time_frame>
    <description>The time (in minutes) from release from the operating room to discharge home</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of nosebleeds from time of drug administration to discharge home</measure>
    <time_frame>approximately 3 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Observational Distress Score at 1 minute</measure>
    <time_frame>1 minute</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Observational Distress Score</measure>
    <time_frame>5minutes</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control patients will receive intranasal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal Midazolam Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 0.2 mg/kg of intranasal midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam Plus Xylocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>midazolam 0.2 mg/kg given intranasally</description>
    <arm_group_label>Nasal Midazolam Only</arm_group_label>
    <arm_group_label>Midazolam Plus Xylocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>xylocaine</intervention_name>
    <description>intransal xylocaine given in conjunction with intranasal midazolam</description>
    <arm_group_label>Midazolam Plus Xylocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline placebo</intervention_name>
    <description>intranasal saline given as placebo</description>
    <arm_group_label>Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children aged 18 months-7 years, scheduled for a minor Ear/Nose/Throat surgical
             procedure requiring mask anesthesia

          2. American Society of Anesthesiologists (ASA) Class 1 or 2

          3. Parent willing and able to provide written informed consent

          4. Parent willing and able to complete the Observed Behavioral Distress (OBD) Visual
             Assessment Scale (VAS)

        Exclusion Criteria:

          1. ASA Class 3 or greater

          2. History of allergy to midazolam or xylocaine

          3. Presence of acute respiratory infection at time of surgery

          4. Parent unwilling or unable to provide informed consent

          5. Parent unwilling or unable to complete the OBD VAS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>david Ullman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bassett Healthcare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jennifer victory, RN</last_name>
    <phone>607-547-6965</phone>
    <email>jennifer.victory@bassett.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>catherine gilmore, RN</last_name>
    <phone>607-547-7926</phone>
    <email>catherine.gilmore@bassett.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bassett Healthcare Network</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Victory, RN</last_name>
      <phone>607-547-6965</phone>
      <email>jennifer.victory@bassett.org</email>
    </contact>
    <contact_backup>
      <last_name>catherine gilmore, RN</last_name>
      <phone>607-547-7926</phone>
      <email>catherine.gilmore@bassett.org</email>
    </contact_backup>
    <investigator>
      <last_name>David ullman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2015</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bassett Healthcare</investigator_affiliation>
    <investigator_full_name>David A Ullman MD</investigator_full_name>
    <investigator_title>Attending Physician - Anesthesiology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Hypnotics and Sedatives</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

